pentoxifylline has been researched along with Hepatic Encephalopathy in 4 studies
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Serum levels of liver enzymes, blood ammonia and prothrombin time and the stage of hepatic encephalopathy were significantly improved in rats treated with dimethylsulfoxide or dimethylthiourea compared to the other treatment groups (p<0." | 3.70 | The hydroxyl radical scavengers dimethylsulfoxide and dimethylthiourea protect rats against thioacetamide-induced fulminant hepatic failure. ( Aeed, H; Avni, Y; Bruck, R; Halpern, Z; Matas, Z; Shirin, H; Zaidel, L, 1999) |
| "Treatment with pentoxifylline was the only factor associated with liver-related complications." | 2.75 | Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. ( Barraud, H; Carbonell, N; Condat, B; Lebrec, D; Moreau, R; Oberti, F; Perarnau, JM; Poynard, T; Ramond, MJ; Renard, P; Saliba, F; Thabut, D, 2010) |
| "Severe alcoholic hepatitis (SAH) is defined by modified Maddrey discriminant function ≥32 or Model for End-Stage Liver Disease (MELD) >21 and/or hepatic encephalopathy." | 2.55 | New paradigms in management of alcoholic hepatitis: a review. ( Goyal, O; Kishore, H; Sidhu, S; Sidhu, SS, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sidhu, SS | 1 |
| Goyal, O | 1 |
| Kishore, H | 1 |
| Sidhu, S | 1 |
| Lebrec, D | 1 |
| Thabut, D | 1 |
| Oberti, F | 1 |
| Perarnau, JM | 1 |
| Condat, B | 1 |
| Barraud, H | 1 |
| Saliba, F | 1 |
| Carbonell, N | 1 |
| Renard, P | 1 |
| Ramond, MJ | 1 |
| Moreau, R | 1 |
| Poynard, T | 1 |
| Bruck, R | 1 |
| Aeed, H | 1 |
| Shirin, H | 1 |
| Matas, Z | 1 |
| Zaidel, L | 1 |
| Avni, Y | 1 |
| Halpern, Z | 1 |
| Koczorek, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial of Pentoxifylline Administration Versus Placebo on Survival in Patients With Cirrhosis and Severe Liver Failure[NCT00162552] | Phase 3 | 342 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
1 review available for pentoxifylline and Hepatic Encephalopathy
| Article | Year |
|---|---|
New paradigms in management of alcoholic hepatitis: a review.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Fecal Microbiota Transplantation; Female | 2017 |
1 trial available for pentoxifylline and Hepatic Encephalopathy
| Article | Year |
|---|---|
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
2 other studies available for pentoxifylline and Hepatic Encephalopathy
| Article | Year |
|---|---|
The hydroxyl radical scavengers dimethylsulfoxide and dimethylthiourea protect rats against thioacetamide-induced fulminant hepatic failure.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Dimethyl Sulfoxide; Free Radical Scaveng | 1999 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; | 2001 |